摘要
目的分析肿瘤标记物检测和核素骨显像对肺癌早期骨转移的诊断价值。方法对65例肺癌患者进行SPECT全身核素骨显像的同时,用化学发光免疫分析法测定血清癌胚抗原(CEA)、可溶性细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇酶(NSE)。另选择肺良性疾病患者70例用化学发光免疫分析法检测血清CEA、CYFR21-1、NSE结果作为对照。结果有骨转移的肺癌患者的血清CEA、CYFR21-1、NSE浓度及阳性率明显高于无骨转移及肺良性疾病患者;骨显像阳性组和骨显像阴性组分别与肺良性疾病组之间CEA、CYFR21-1、NSE检测结果存在显著性差异(P<0.01)。结论常规做全身骨显像,对于临床的判断、分期和确定治疗方法具有重要意义。
Objective The purpose is to analyze the value of detection of serum tumor markers and nuclein bone imaging in the diagnosis of early bone metastasis in lung cancer. Methods 70 benign lung disease patients as a comparative group and their serum CEA, CYFR21-1, NSE were detected with a chemical luminiferous were selected immunity analysis method. For 65 regular lung cancer patients, their nuclide bone imaging of the whole body with SPECT was made, and at the same time, their serum CEA, CYFR21-1, and NSE were surveyed. Results The positive rate and density of serum CEA, CYFR21-1, NSE of lung cancer patients with bone metastasis are obviously higher than those of patients without bone metastasis or with benign lung disease. Meanwhile, when the positive group of bone imaging and the negative group of bone imaging are compared with the group of benign lung disease respectively, CEA, CYFR21-1 and NSE showed significant difference（ P 〈 0.01 ）. Conclusion The detection of serum tumor marker is helpful to make clear the nature of pathological changes in the lung cancer patients whose nuclein bone imagings are unusual.
出处
《山东医学高等专科学校学报》
2006年第5期325-327,共3页
Journal of Shandong Medical College
关键词
肺癌
肿瘤标记物
核素
骨转移
lung cancer
tumor marker
Nuclide
Bone metastasis
